Sharmila Dorbala

List of Publications by Year
in descending order

209 papers	15,610 citations	19636 61 h-index	18115 120 g-index
217 all docs	217 docs citations	217 times ranked	9041 citing authors

#	Article	IF	Citations
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
2	Improved Cardiac Risk Assessment With Noninvasive Measures of Coronary Flow Reserve. Circulation, 2011, 124, 2215-2224.	1.6	710
3	Cardiac Positron Emission Tomography Enhances Prognostic Assessments of Patients With Suspected Cardiac Sarcoidosis. Journal of the American College of Cardiology, 2014, 63, 329-336.	1.2	572
4	Anatomic Versus Physiologic Assessment of Coronary Artery Disease. Journal of the American College of Cardiology, 2013, 62, 1639-1653.	1.2	495
5	Effects of Sex on Coronary Microvascular Dysfunction and Cardiac Outcomes. Circulation, 2014, 129, 2518-2527.	1.6	467
6	ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. Journal of Nuclear Cardiology, 2016, 23, 1187-1226.	1.4	450
7	AL (Light-Chain) Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 1323-1341.	1.2	443
8	Association Between Coronary Vascular Dysfunction and Cardiac Mortality in Patients With and Without Diabetes Mellitus. Circulation, 2012, 126, 1858-1868.	1.6	435
9	Global Coronary Flow Reserve Is Associated With Adverse Cardiovascular Events Independently of Luminal Angiographic Severity and Modifies the Effect of Early Revascularization. Circulation, 2015, 131, 19-27.	1.6	410
10	Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. European Heart Journal, 2018, 39, 840-849.	1.0	390
11	Interrelation of Coronary Calcification, Myocardial Ischemia, and Outcomes in Patients With Intermediate Likelihood of Coronary Artery Disease. Circulation, 2008, 117, 1693-1700.	1.6	346
12	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	1.6	312
13	Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1652-1662.	3.3	252
14	Deep Learning for Prediction of Obstructive Disease From Fast Myocardial Perfusion SPECT. JACC: Cardiovascular Imaging, 2018, 11, 1654-1663.	2.3	246
15	Diagnostic Accuracy of Rubidium-82 Myocardial Perfusion Imaging With Hybrid Positron Emission Tomography/Computed Tomography in the Detection of Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 49, 1052-1058.	1.2	243
16	Reproducibility and Accuracy of Quantitative Myocardial Blood Flow Assessment with ^{82}Rb PET: Comparison with ^{13}N-Ammonia PET. Journal of Nuclear Medicine, 2009, 50, 1062-1071.	2.8	242
17	Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging Guidelines: Instrumentation, Acquisition, Processing, and Interpretation. Journal of Nuclear Cardiology, 2018, 25, 1784-1846.	1.4	241
18	Incremental Prognostic Value of Gated Rb-82 Positron Emission Tomography Myocardial Perfusion Imaging Over Clinical Variables and Rest LVEF. JACC: Cardiovascular Imaging, 2009, 2, 846-854.	2.3	239

#	Article	IF	Citations
19	Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease. Circulation, 2017, 135, 566-577.	1.6	231
20	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	1.4	230
21	Preserved Coronary Flow Reserve Effectively Excludes High-Risk Coronary Artery Disease on Angiography. Journal of Nuclear Medicine, 2014, 55, 248-255.	2.8	216
22	Prognostic Value of Stress Myocardial Perfusion Positron Emission Tomography. Journal of the American College of Cardiology, 2013, 61, 176-184.	1.2	204
23	Integrated Noninvasive Physiological Assessment of Coronary Circulatory Function and Impact on Cardiovascular Mortality in Patients With Stable Coronary Artery Disease. Circulation, 2017, 136, 2325-2336.	1.6	193
24	Joint SNMMIâ€"ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. Journal of Nuclear Medicine, 2017, 58, 1341-1353.	2.8	187
25	Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2018, 11, e007030.	1.3	187
26	SNMMI/ASNC/SCCT Guideline for Cardiac SPECT/CT and PET/CT 1.0. Journal of Nuclear Medicine, 2013, 54, 1485-1507.	2.8	184
27	Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. Journal of Nuclear Cardiology, 2017, 24, 86-99.	1.4	170
28	Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. Journal of Nuclear Medicine, 2018, 59, 273-293.	2.8	163
29	Value of vasodilator left ventricular ejection fraction reserve in evaluating the magnitude of myocardium at risk and the extent of angiographic coronary artery disease: a 82Rb PET/CT study. Journal of Nuclear Medicine, 2007, 48, 349-58.	2.8	163
30	How to Image Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1368-1383.	2.3	156
31	Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. Journal of Nuclear Cardiology, 2018, 25, 269-297.	1.4	151
32	Coronary Microvascular Dysfunction Is Related to Abnormalities in Myocardial Structure and Function in Cardiac Amyloidosis. JACC: Heart Failure, 2014, 2, 358-367.	1.9	148
33	How to Image Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2014, 7, 552-562.	1.3	138
34	Interaction of Impaired Coronary Flow Reserve and Cardiomyocyte Injury on Adverse Cardiovascular Outcomes in Patients Without Overt Coronary Artery Disease. Circulation, 2015, 131, 528-535.	1.6	135
35	Joint SNMMIâ€"ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. Journal of Nuclear Cardiology, 2017, 24, 1741-1758.	1.4	132
36	Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis. Journal of the American College of Cardiology, 2020, 75, 2851-2862.	1.2	131

#	Article	IF	Citations
37	International Impact of COVID-19 on the Diagnosis of Heart Disease. Journal of the American College of Cardiology, 2021, 77, 173-185.	1.2	130
38	Epidemiology of Cardiac Amyloidosis–Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circulation: Heart Failure, 2019, 12, e005407.	1.6	126
39	Patient-Centered Imaging. Journal of the American College of Cardiology, 2014, 63, 1480-1489.	1.2	122
40	Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. Journal of Nuclear Cardiology, 2018, 25, 1136-1146.	1.4	121
41	Deep Learning Analysis of Upright-Supine High-Efficiency SPECT Myocardial Perfusion Imaging for Prediction of Obstructive Coronary Artery Disease: A Multicenter Study. Journal of Nuclear Medicine, 2019, 60, 664-670.	2.8	113
42	18 F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits. Circulation: Cardiovascular Imaging, 2015, 8, .	1.3	107
43	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2–Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	0.7	107
44	Coronary Microvascular Dysfunction and Cardiovascular Risk in Obese Patients. Journal of the American College of Cardiology, 2018, 72, 707-717.	1.2	103
45	Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. European Heart Journal Cardiovascular Imaging, 2015, 16, 900-909.	0.5	100
46	A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Journal of Nuclear Cardiology, 2018, 25, 298-319.	1.4	97
47	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2–Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	1.4	97
48	Comparison of Fully Automated Computer Analysis and Visual Scoring for Detection of Coronary Artery Disease from Myocardial Perfusion SPECT in a Large Population. Journal of Nuclear Medicine, 2013, 54, 221-228.	2.8	96
49	State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. Journal of Nuclear Cardiology, 2019, 26, 158-173.	1.4	82
50	Influence of Sex on Risk Stratification With Stress Myocardial Perfusion Rb-82 Positron Emission Tomography. Journal of the American College of Cardiology, 2013, 62, 1866-1876.	1.2	80
51	Assessment of myocardial perfusion and function with PET and PET/CT. Journal of Nuclear Cardiology, 2010, 17, 498-513.	1.4	77
52	A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. European Heart Journal Cardiovascular Imaging, 2017, 18, 1073-1089.	0.5	74
53	Rationale and design of the REgistry of Fast Myocardial Perfusion Imaging with NExt generation SPECT (REFINE SPECT). Journal of Nuclear Cardiology, 2020, 27, 1010-1021.	1.4	74
54	Cardiac PET Perfusion: Prognosis, Risk Stratification, and Clinical Management. Seminars in Nuclear Medicine, 2014, 44, 344-357.	2.5	72

#	Article	IF	Citations
55	Myocardial perfusion imaging in women for the evaluation of stable ischemic heart disease—state-of-the-evidence and clinical recommendations. Journal of Nuclear Cardiology, 2017, 24, 1402-1426.	1.4	71
56	Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015. JAMA Cardiology, 2018, 3, 865.	3.0	71
57	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	0.7	70
58	5-Year Prognostic Value of Quantitative Versus Visual MPI in Subtle Perfusion Defects. JACC: Cardiovascular Imaging, 2020, 13, 774-785.	2.3	70
59	Machine learning predicts per-vessel early coronary revascularization after fast myocardial perfusion SPECT: results from multicentre REFINE SPECT registry. European Heart Journal Cardiovascular Imaging, 2020, 21, 549-559.	0.5	70
60	Prognostic Value of Coronary Flow Reserve in Patients with Dialysis-Dependent ESRD. Journal of the American Society of Nephrology: JASN, 2016, 27, 1823-1829.	3.0	67
61	Incremental Prognostic Value of Myocardial Perfusion Imaging in Patients Referred to Stress Single-Photon Emission Computed Tomography With Renal Dysfunction. Circulation: Cardiovascular Imaging, 2009, 2, 429-436.	1.3	62
62	Prognostic Value of PET Myocardial Perfusion Imaging in Obese Patients. JACC: Cardiovascular Imaging, 2014, 7, 278-287.	2.3	62
63	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
64	Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage. Kidney International, 2018, 93, 501-509.	2.6	59
65	Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2021, 23, 895-905.	2.9	57
66	Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI. Journal of Nuclear Cardiology, 2020, 27, 1022-1029.	1.4	56
67	Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2019, 12, e008975.	1.3	54
68	Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body ^{18}F-Florbetapir PET/CT. Journal of Nuclear Medicine, 2019, 60, 1234-1239.	2.8	54
69	Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment. Circulation, 2020, 141, 21-33.	1.6	54
70	Yield of Downstream Tests After Exercise Treadmill Testing. Journal of the American College of Cardiology, 2014, 63, 1264-1274.	1.2	51
71	Absolute Quantitation of Cardiac ^{99m}Tc-Pyrophosphate Using Cadmium-Zinc-Telluride—Based SPECT/CT. Journal of Nuclear Medicine, 2021, 62, 716-722.	2.8	51
72	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	1.3	48

#	Article	IF	Citations
73	Effect of Body Mass Index on Left Ventricular Cavity Size and Ejection Fraction. American Journal of Cardiology, 2006, 97, 725-729.	0.7	47
74	Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure. European Heart Journal, 2020, 41, 2366-2375.	1.0	47
75	Relative Apical Sparing of Myocardial Longitudinal Strain Is Explained by Regional Differences in Total Amyloid Mass Rather Than the Proportion ofÂAmyloid Deposits. JACC: Cardiovascular Imaging, 2019, 12, 1165-1173.	2.3	45
76	Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT. Radiology, 2019, 291, 330-337.	3.6	45
77	Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies. Heart Failure Reviews, 2017, 22, 455-464.	1.7	44
78	Clinical Deployment of Explainable Artificial Intelligence of SPECT for Diagnosis of Coronary Artery Disease. JACC: Cardiovascular Imaging, 2022, 15, 1091-1102.	2.3	44
79	Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic. Journal of the American College of Cardiology, 2020, 75, 3177-3183.	1.2	41
80	Improved Quantification of CardiacÂAmyloid Burden in SystemicÂLight ChainÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1325-1336.	2.3	41
81	Approaches to Reducing Radiation Dose from Radionuclide Myocardial Perfusion Imaging. Journal of Nuclear Medicine, 2015, 56, 592-599.	2.8	39
82	Prognostically safe stress-only single-photon emission computed tomography myocardial perfusion imaging guided by machine learning: report from REFINE SPECT. European Heart Journal Cardiovascular Imaging, 2021, 22, 705-714.	0.5	38
83	Coronary vasodilator reserve and Framingham risk scores in subjects at risk for coronary artery disease. Journal of Nuclear Cardiology, 2006, 13, 761-767.	1.4	36
84	Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. Journal of the American Heart Association, 2017, 6, .	1.6	35
85	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	1.4	34
86	Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2022, 23, 1029-1039.	0.5	33
87	Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World. JACC: Cardiovascular Imaging, 2021, 14, 1787-1799.	2.3	32
88	Fully automated wall motion and thickening scoring system for myocardial perfusion SPECT: Method development and validation in large population. Journal of Nuclear Cardiology, 2012, 19, 291-302.	1.4	29
89	Guidance and best practices for reestablishment of non-emergent care in nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An information statement from ASNC, IAEA, and SNMMI. Journal of Nuclear Cardiology, 2020, 27, 1855-1862.	1.4	28
90	Impact of Early Revascularization on Major Adverse Cardiovascular Events inÂRelation to Automatically QuantifiedÂIschemia. JACC: Cardiovascular Imaging, 2021, 14, 644-653.	2.3	28

#	Article	IF	Citations
91	Contemporary Cardiac SPECT Imaging—Innovations and Best Practices: An Information Statement from the American Society of Nuclear Cardiology. Journal of Nuclear Cardiology, 2018, 25, 1847-1860.	1.4	27
92	Concomitant Transthyretin Amyloidosis and Severe Aortic Stenosis in Elderly Indian Population. JACC: CardioOncology, 2021, 3, 565-576.	1.7	27
93	ACR Appropriateness Criteria Asymptomatic Patient at Risk for Coronary Artery Disease. Journal of the American College of Radiology, 2014, 11, 12-19.	0.9	26
94	Dose reduction in half-time myocardial perfusion SPECT-CT with multifocal collimation. Journal of Nuclear Cardiology, 2016, 23, 657-667.	1.4	26
95	Determining a minimum set of variables for machine learning cardiovascular event prediction: results from REFINE SPECT registry. Cardiovascular Research, 2022, 118, 2152-2164.	1.8	26
96	Coronary microvascular dysfunction, left ventricular remodeling, and clinical outcomes in aortic stenosis. Journal of Nuclear Cardiology, 2021, 28, 579-588.	1.4	24
97	Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders. JACC: Cardiovascular Imaging, 2021, 14, 2212-2220.	2.3	24
98	Myocardial Ischemic Burden and Differences in Prognosis Among Patients With and Without Diabetes: Results From the Multicenter International REFINE SPECT Registry. Diabetes Care, 2020, 43, 453-459.	4.3	21
99	Cardiac Imaging in the Post-ISCHEMIA Trial Era. JACC: Cardiovascular Imaging, 2020, 13, 1815-1833.	2.3	21
100	Transient ischaemic dilation and post-stress wall motion abnormality increase risk in patients with less than moderate ischaemia: analysis of the REFINE SPECT registry. European Heart Journal Cardiovascular Imaging, 2020, 21, 567-575.	0.5	21
101	Diagnostic safety of a machine learning-based automatic patient selection algorithm for stress-only myocardial perfusion SPECT. Journal of Nuclear Cardiology, 2022, 29, 2295-2307.	1.4	21
102	Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19. Journal of the American College of Cardiology, 2022, 79, 2001-2017.	1.2	21
103	Myocardial Scar But Not Ischemia Is Associated With Defibrillator Shocks and Sudden Cardiac Death in Stable Patients With Reduced Left Ventricular Ejection Fraction. JACC: Clinical Electrophysiology, 2018, 4, 1200-1210.	1.3	20
104	Targeted Nuclear Imaging Probes for Cardiac Amyloidosis. Current Cardiology Reports, 2017, 19, 59.	1.3	19
105	Mortality From Heart Failure and Dementia in the United States: CDC WONDER 1999–2016. Journal of Cardiac Failure, 2019, 25, 125-129.	0.7	19
106	Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans. European Journal of Heart Failure, 2021, 23, 1290-1295.	2.9	19
107	Low coronary flow relative to myocardial mass predicts heart failure in symptomatic hypertensive patients with no obstructive coronary artery disease. European Heart Journal, 2022, 43, 3323-3331.	1.0	19
108	Accuracy and Reproducibility of Myocardial Blood Flow Quantification by Single Photon Emission Computed Tomography Imaging in Patients With Known or Suspected Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2022, 15, .	1.3	19

#	Article	IF	Citations
109	Clinical applications of radionuclide imaging in the evaluation and management of patients with congenital heart disease. Journal of Nuclear Cardiology, 2016, 23, 45-63.	1.4	18
110	Coronary microvascular dysfunction in patients with psoriasis. Journal of Nuclear Cardiology, 2022, 29, 37-42.	1.4	18
111	Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H1158-H1166.	1.5	17
112	Upper reference limits of transient ischemic dilation ratio for different protocols on new-generation cadmium zinc telluride cameras: A report from REFINE SPECT registry. Journal of Nuclear Cardiology, 2020, 27, 1180-1189.	1.4	17
113	Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus. Journal of the American Heart Association, 2021, 10, e018555.	1.6	17
114	Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe. Open Heart, 2021, 8, e001681.	0.9	17
115	Prognostic value of SPECT myocardial perfusion imaging in patients with elevated cardiac troponin I levels and atypical clinical presentation. Journal of Nuclear Cardiology, 2007, 14, 53-58.	1.4	16
116	Prognostic value of Rb-82 positron emission tomography myocardial perfusion imaging in coronary artery bypass patients. European Heart Journal Cardiovascular Imaging, 2014, 15, 787-792.	0.5	16
117	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	1.3	16
118	Association of Myocardial Blood Flow Reserve With Adverse Left Ventricular Remodeling in Patients With Aortic Stenosis. JAMA Cardiology, 2022, 7, 93.	3.0	16
119	Prognostic value of coronary CTA vs. exercise treadmill testing: results from the Partners registry. European Heart Journal Cardiovascular Imaging, 2015, 16, 1338-1346.	0.5	15
120	Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic. Annals of Thoracic Surgery, 2020, 110, 733-740.	0.7	15
121	The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types. Blood Reviews, 2021, 45, 100720.	2.8	15
122	Contemporary Cardiac SPECT Imagingâ€"Innovations and Best Practices: An Information Statement from the American Society of Nuclear Cardiology. Circulation: Cardiovascular Imaging, 2018, 11, e000020.	1.3	14
123	Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1998-2009.	3.3	14
124	Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI. Journal of Nuclear Medicine, 2020, , jnumed.120.246686.	2.8	14
125	Handling missing values in machine learning to predict patient-specific risk of adverse cardiac events: Insights from REFINE SPECT registry. Computers in Biology and Medicine, 2022, 145, 105449.	3.9	14
126	Gender Differences in Radiation Dose FromÂNuclear Cardiology Studies AcrossÂtheÂWorld. JACC: Cardiovascular Imaging, 2016, 9, 376-384.	2.3	13

#	Article	IF	Citations
127	Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership. Canadian Journal of Cardiology, 2020, 36, 971-976.	0.8	13
128	Prognostic Value of Phase Analysis for Predicting Adverse Cardiac Events Beyond Conventional Single-Photon Emission Computed Tomography Variables: Results From the REFINE SPECT Registry. Circulation: Cardiovascular Imaging, 2021, 14, e012386.	1.3	13
129	Reproducibility and Repeatability of Assessment of Myocardial Light Chain Amyloidosis Burden Using 18F-Florbetapir PET/CT. Journal of Nuclear Cardiology, 2021, 28, 2004-2010.	1.4	12
130	Quantitative Bone-Avid Tracer SPECT/CT for Cardiac Amyloidosis: A Crucial Step Forward. JACC: Cardiovascular Imaging, 2020, 13, 1364-1367.	2.3	12
131	Guidance and Best Practices for Reestablishment of Non-Emergent Care in Nuclear Cardiology Laboratories During the Coronavirus Disease 2019 (COVID-19) Pandemic: An Information Statement from ASNC, IAEA, and SNMMI. Journal of Nuclear Medicine Technology, 2021, 49, 13-18.	0.4	12
132	The role of positron emission tomography in the evaluation of myocardial ischemia in women. Journal of Nuclear Cardiology, 2016, 23, 1008-1015.	1.4	11
133	Automated quantitative analysis of CZT SPECT stratifies cardiovascular risk in the obese population: Analysis of the REFINE SPECT registry. Journal of Nuclear Cardiology, 2022, 29, 727-736.	1.4	11
134	Reduction of cardiac imaging tests during the COVID-19 pandemic: The case of Italy. Findings from the IAEA Non-invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID). International Journal of Cardiology, 2021, 341, 100-106.	0.8	10
135	Impact of COVID-19 on Diagnostic Cardiac Procedural Volume in Oceania: The IAEA Non-Invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID). Heart Lung and Circulation, 2021, 30, 1477-1486.	0.2	10
136	Quantitative molecular imaging of cardiac amyloidosis: The journey has begun. Journal of Nuclear Cardiology, 2016, 23, 751-753.	1.4	9
137	Reducing radiation dose from myocardial perfusion imaging in subjects with complex congenital heart disease. Journal of Nuclear Cardiology, 2021, 28, 1395-1408.	1.4	9
138	Appropriateness of inpatient stress testing: Implications for development of clinical decision support mechanisms and future criteria. Journal of Nuclear Cardiology, 2021, 28, 1988-1997.	1.4	9
139	Role of Exercise Treadmill Testing in the Assessment of Coronary Microvascular Disease. JACC: Cardiovascular Imaging, 2022, 15, 312-321.	2.3	9
140	Worldwide Variation in the Use of Nuclear Cardiology Camera Technology, Reconstruction Software, and Imaging Protocols. JACC: Cardiovascular Imaging, 2021, 14, 1819-1828.	2.3	9
141	Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy. JACC: CardioOncology, 2021, 3, 580-586.	1.7	9
142	ASNC's thoughts on the AHA/ACC chest pain guidelines. Journal of Nuclear Cardiology, 2022, 29, 19-23.	1.4	9
143	Utility of multimodality imaging in diagnosis and follow-up of aortitis. Journal of Nuclear Cardiology, 2016, 23, 590-595.	1.4	8
144	Prognostic significance of blood pressure response during vasodilator stress Rb-82 positron emission tomography myocardial perfusion imaging. Journal of Nuclear Cardiology, 2017, 24, 1966-1975.	1.4	8

#	Article	IF	Citations
145	Inter-observer reproducibility and intra-observer repeatability in 99mTc-pyrophosphate scan interpretation for diagnosis of transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology, 2022, 29, 440-446.	1.4	8
146	A Clinical Tool to Identify Candidates for Stress-First Myocardial Perfusion Imaging. JACC: Cardiovascular Imaging, 2020, 13, 2193-2202.	2.3	8
147	Positron emission tomography for cardiac amyloidosis: Timing matters!. Journal of Nuclear Cardiology, 2022, 29, 790-797.	1.4	8
148	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	0.7	8
149	Coronary vasomotor dysfunction portends worse outcomes in patients with breast cancer. Journal of Nuclear Cardiology, 2022, 29, 3072-3081.	1.4	8
150	Coronary vasomotor dysfunction in cancer survivors treated with thoracic irradiation. Journal of Nuclear Cardiology, 2021, 28, 2976-2987.	1.4	7
151	Guidance and Best Practices for Nuclear Cardiology Laboratories During the COVID-19 Pandemic. Circulation: Cardiovascular Imaging, 2020, 13, e011761.	1.3	7
152	Quantitation of Poststress Change in Ventricular Morphology Improves Risk Stratification. Journal of Nuclear Medicine, 2021, 62, 1582-1590.	2.8	7
153	Explainable Deep Learning Improves Physician Interpretation of Myocardial Perfusion Imaging. Journal of Nuclear Medicine, 2022, , jnumed.121.263686.	2.8	7
154	Machine learning to predict abnormal myocardial perfusion from pre-test features. Journal of Nuclear Cardiology, 2022, 29, 2393-2403.	1.4	7
155	True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis. Haematologica, 2018, 103, e374-e376.	1.7	6
156	Prognostic value of vasodilator response using rubidium-82 positron emission tomography myocardial perfusion imaging in patients with coronary artery disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 538-548.	3.3	6
157	Multimodality Imaging in the Evaluation and Management of Cardiac Amyloidosis. Seminars in Nuclear Medicine, 2020, 50, 295-310.	2.5	6
158	A Policy Statement on Cardiovascular Test Substitution and Authorization. Journal of the American College of Cardiology, 2021, 78, 1385-1389.	1.2	6
159	Comparison of diabetes to other prognostic predictors among patients referred for cardiac stress testing: A contemporary analysis from the REFINE SPECT Registry. Journal of Nuclear Cardiology, 2022, 29, 3003-3014.	1.4	6
160	Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC: Cardiovascular Imaging, 2022, 15, 594-603.	2.3	6
161	Update on guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: Emphasis on transition to chronic endemic state. An information statement from ASNC, IAEA, and SNMMI. Journal of Nuclear Cardiology, 2022, 29, 2013-2018.	1.4	6
162	Stress Myocardial Perfusion PET Provides Incremental Risk Prediction in Patients with and Patients without Diabetes. Radiology: Cardiothoracic Imaging, 2019, 1, e180018.	0.9	5

#	Article	IF	Citations
163	Complexities and Pitfalls in Cardiac Amyloidosis. Circulation, 2020, 142, 409-415.	1.6	5
164	ASNC Imaging Indications (ASNC-I2): Multisocietal indications for radionuclide imaging in the multimodality context—Series rationale and methodology. Journal of Nuclear Cardiology, 2022, 29, 2667-2678.	1.4	5
165	Changing the trajectory of ischemic heart disease in women: Role of imaging. Journal of Nuclear Cardiology, 2016, 23, 973-975.	1.4	4
166	Molecular phenotyping of infiltrative cardiomyopathies: The future. Journal of Nuclear Cardiology, 2019, 26, 154-157.	1.4	4
167	Normal Variants and Pitfalls in Cardiac PET/CT. Seminars in Nuclear Medicine, 2021, 51, 441-457.	2.5	4
168	Response to Letter Regarding Article, "Effects of Sex on Coronary Microvascular Dysfunction and Cardiac Outcomes". Circulation, 2015, 131, e376.	1.6	3
169	Clinical value of hyperemic left ventricular systolic function in vasodilator stress testing. Journal of Nuclear Cardiology, 2017, 24, 1002-1006.	1.4	3
170	Imaging of cardiac amyloidosis: Will this become a unique application for dual-isotope imaging?. Journal of Nuclear Cardiology, 2020, 27, 38-40.	1.4	3
171	Transthyretin cardiac amyloidosis in patients with severe aortic stenosis. European Heart Journal, 2020, 41, 2768-2770.	1.0	3
172	ASNC Statements of Principles on the Issue of Multimodality Imaging. Journal of Nuclear Cardiology, 2021, 28, 2456-2457.	1.4	3
173	Prevalence and predictors of automatically quantified myocardial ischemia within a multicenter international registry. Journal of Nuclear Cardiology, 2022, 29, 3221-3232.	1.4	3
174	Imaging cardiac amyloidosis: An opportunity for nuclear cardiology. Journal of Nuclear Cardiology, 2014, 21, 1043-1044.	1.4	2
175	Comparison of the Use of Downstream Tests After Exercise Treadmill Testing by Cardiologists Versus Noncardiologists. American Journal of Cardiology, 2014, 114, 305-311.	0.7	2
176	Utility of multimodality imaging in suspected prosthetic valve endocarditis. Journal of Nuclear Cardiology, 2016, 23, 316-320.	1.4	2
177	Imaging cardiac amyloidosis: Patient page. Journal of Nuclear Cardiology, 2019, 26, 217-221.	1.4	2
178	Geographic variation in public interest about amyloidosis in the United States and English speaking countries. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 210-212.	1.4	2
179	Effect of Concurrent Dementia on Heart Failure Hospital Outcomes: Nationwide Inpatient Sample (2007–2014). Journal of Cardiac Failure, 2021, 27, 258-260.	0.7	2
180	Transthyretin Cardiac Amyloidosis in the Elderly—Tip of a Heart Failure Iceberg?. JAMA Cardiology, 2021, 6, 979.	3.0	2

#	ARTICLE	IF	CITATIONS
181	Trends and Outcomes of Patients With Amyloid Cardiomyopathy Listed for Heart Transplantation. Canadian Journal of Cardiology, 2022, 38, 1263-1270.	0.8	2
182	Differences in Prognostic Value of Myocardial Perfusion Single-Photon Emission Computed Tomography Using High-Efficiency Solid-State Detector Between Men and Women in a Large International Multicenter Study. Circulation: Cardiovascular Imaging, 2022, 15, .	1.3	2
183	Advances in Myocardial Perfusion Imaging. Progress in Cardiovascular Diseases, 2015, 57, 535-536.	1.6	1
184	Collegial pressure and patient-centered shared-decision making: A case-based ethics discussion. Journal of Nuclear Cardiology, 2015, 22, 920-922.	1.4	1
185	Responsibility for follow-up of abnormal findings in myocardial perfusion imaging: A case-based ethics discussion. Journal of Nuclear Cardiology, 2015, 22, 927-931.	1.4	1
186	How to approach an inappropriately ordered myocardial perfusion stress study: A case-based ethics discussion. Journal of Nuclear Cardiology, 2015, 22, 923-926.	1.4	1
187	Frontiers of Nuclear Cardiology. Cardiology Clinics, 2016, 34, xiii.	0.9	1
188	Apical to Base Gradient of Technetium-99m Pyrophosphate Myocardial Counts in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2018, 11, 243-246.	2.3	1
189	An antibody against pre-amyloid oligomers: a potential clinical tool or merely an intriguing observation?. European Heart Journal, 2020, 41, 1271-1272.	1.0	1
190	SPECT/CT quantification of lower limb perfusion: The next frontier in radionuclide perfusion imaging?. Journal of Nuclear Cardiology, 2020, 27, 1934-1938.	1.4	1
191	(18)F-sodium fluoride PET in multiple myeloma: Linking cancer to atherosclerosis?. Journal of Nuclear Cardiology, 2021, 28, 3055-3057.	1.4	1
192	Recent clinical trials support continued emphasis on patient-first over modality-first approaches to initial test selection in patients with stable ischemic heart disease. Journal of Nuclear Cardiology, 2023, 30, 1739-1744.	1.4	1
193	Women leaders: transforming the culture in cardiology. Open Heart, 2022, 9, e001967.	0.9	1
194	Transmural perfusion: A new direction for myocardial blood flow. Journal of Nuclear Cardiology, 2022, 29, 1952-1955.	1.4	1
195	Quantifying the burden of cardiac amyloid: The future is about numbers!. Journal of Nuclear Cardiology, 2023, 30, 112-115.	1.4	1
196	Highlights of the 12th International Conference on Nuclear Cardiology and Cardiac CT. European Heart Journal Cardiovascular Imaging, 2015, 16, 959-965.	0.5	0
197	What is this image? 2018: image 6 result. Journal of Nuclear Cardiology, 2018, 25, 720-723.	1.4	0
198	Molecular Imaging of Cardiac Amyloidosis. Current Cardiovascular Imaging Reports, 2018, 11, 1.	0.4	0

#	Article	IF	Citations
199	The new normal. Journal of Nuclear Cardiology, 2020, 27, 1418-1419.	1.4	0
200	A letter to fellows in nuclear cardiology. Journal of Nuclear Cardiology, 2020, 27, 1901-1902.	1.4	0
201	2020: A Year of ASNC â€œFirstsâ€• Journal of Nuclear Cardiology, 2020, 27, 2439-2440.	1.4	0
202	Phenotyping of Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2020, 13, e010785.	1.3	0
203	Evaluating Prognosis in AL Amyloidosis. JACC: CardioOncology, 2020, 2, 232-235.	1.7	0
204	Social media in nuclear cardiology. Journal of Nuclear Cardiology, 2020, 27, 703-704.	1.4	0
205	Nuclear cardiology in the information age. Journal of Nuclear Cardiology, 2020, 27, 342-344.	1.4	0
206	Advancing the mission of cardiovascular molecular imaging. Journal of Nuclear Cardiology, 2023, 30, 2266-2267.	1.4	0
207	Progress in Cardiac Imaging Uncovers the Epidemiology of Wild-Type Transthyretin Amyloid Cardiomyopathy. JACC: CardioOncology, 2021, 3, 547-549.	1.7	0
208	Letter by Falk et al Regarding Article, â€œFalse-Positive 99m Technetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathyâ€• Circulation: Heart Failure, 2022, 15, 101161CIRCHEARTFAILURE121008636.	1.6	0
209	2021 SNMMI Highlights Lecture: Cardiovascular Track.. Journal of Nuclear Medicine, 2022, 63, 11N-16N.	2.8	0